Skip to main
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 47%
Buy 35%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences is a leading company in the development and marketing of therapies for life-threatening infectious diseases, with a strong focus on HIV and hepatitis B and C treatments. The recent acquisition of Pharmasset has expanded Gilead's portfolio to include the highly successful hepatitis C drug Sovaldi, as well as new cancer therapies. The company's strong financial standing, diverse pipeline of innovative treatments, and commitment to health equity make it a promising investment opportunity with limited near-term risks.

Bears say

Gilead Sciences is a biopharmaceutical company with a favorable leadership position and pricing power in the HIV market, sustainable volumes in the HCV market, and potential for blockbuster drugs in the oncology market. However, their commitment to long-acting combos and HIV cure treatments may not result in significant financial benefits until the 2030s, and their transparency and governance practices have room for improvement. Their recent acquisitions have the potential to drive future growth, but their current decline in sales and profits may hamper short-term performance.

Gilead Sciences (GILD) has been analyzed by 17 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 35% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 17 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $153.24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $153.24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.